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Hemodialysis (HD) patients are subject to an enormous
excess of cardiovascular morbidity and mortality. This
appears to be largely driven by factors that are different from
those at play in the general population. Chronic HD patients
are already primed by a large number of structural and
functional peripheral vascular and cardiac abnormalities to
experience demand myocardial ischemia. Conventional HD is
capable of inducing myocardial ischemia. Recurrent ischemic
insults lead to myocardial functional and structural changes,
eventually resulting in fixed systolic dysfunction and heart
failure (conferring a dismal prognosis for patients
undergoing dialysis). Modifications of the HD process to
improve the hemodynamic tolerability of the treatment have
been shown to reduce the perturbation of myocardial blood
flow and functional evidence of dialysis-induced ischemia.
Although it is uncomfortable to consider that much of the
observed disease burden in HD patients may be an artifact of
current dialysis treatment regimes, understanding the role
that conventional dialysis plays in the pathophysiology of
cardiac injury in HD patients has the potential to provide us
with additional dialysis, and non-dialysis, based novel
therapeutic targets to reduce currently excessive rates of
cardiovascular morbidity and mortality.
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It is well recognized that dialysis patients display hugely
elevated rates of cardiac mortality.1 It is also becoming
appreciated that this rate of cardiovascular attrition is not
driven by the same variety of risk factors, or pathophysio-
logical processes that are important in the general popu-
lation.2 Classical complicated atherosclerotic disease appears
not to be the predominant mode of death in hemodialysis
(HD) patients. Records from the US Renal Data System have
shown that HD is an independent risk factor for the
development of both de novo and recurrent heart failure
with a 2-year mortality after a diagnosis of congestive heart
failure as high as 51%,3 making it the one of the most
common causes of cardiovascular mortality in this patient
group. In addition, a significant percentage of cardiac
mortality is due to sudden death, and sudden death appears
to be temporally related to the dialysis procedure.4 Abnormal
ventricular morphology and function appear to be major
determinants of cardiac arrhythmias in this patient group.
It has long been suspected that myocardial ischemia may be
precipitated by HD. Short intermittent HD treatments exert
significant hemodynamic effects, and 20–30% of treatments are
additionally complicated by episodes of significant intradialytic
hypotension (IDH).5 In conjunction with this, HD patients are
particularly susceptible to myocardial ischemia. In addition to
the high prevalence of coronary artery atheroma, diabetic
dialysis patients have been shown to have a reduced coronary
flow reserve in the absence of coronary vessel lesions.6 HD
patients characteristically also exhibit left ventricular hyper-
trophy, reduced peripheral arterial compliance, impaired
microcirculation,7 and ineffective vasoregulation (in the face
of HD coupled with ultrafiltration). All of these factors also
predispose to demand cardiac ischemia. This article aims to
review the evolving concepts surrounding HD-induced acute,
recurrent myocardial ischemia and its contribution to the
genesis of the observed constellation of cardiac abnormalities in
patients undergoing maintenance HD and longer-term adverse
cardiac outcomes.
MYOCARDIAL ISCHEMIC POTENTIAL IN HD PATIENTS
The first report of silent ST-segment depression during
dialysis dates back to 1989.8 However, this concept of
subclinical ischemia (occurring without acute atheroschlero-
tic plaque rupture) has received remarkably little attention,
despite its theoretical plausibility. Short intermittent HD
treatments exert significant hemodynamic effects (Figure 1),
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and 20–30% of treatments are complicated by IDH. In
conjunction with this, HD patients are particularly suscep-
tible to myocardial ischemia. This is as a result of large vessel
and microcirculatory changes resulting in a reduced coronary
flow reserve. This determines the ability to increase blood
flow to the myocardium during increased demand. In part,
this may be due to left ventricular hypertrophy, present in up
to around 75% of patients on dialysis, which reduces
coronary flow reserve and is associated with a myocyte-
capillary mismatch. Increased peripheral artery stiffness is
also recognized to have an adverse effect on myocardial
perfusion and reduces the ischemic threshold.9 Therefore, left
ventricular hypertrophy in tandem with increased vascular
stiffness may lead to a propensity to reduced myocardial
blood flow (MBF), and particularly subendocardial MBF.
In non-uremic patients, blood pressure (BP) is largely
independent of cardiac output, due to the full gamut of
functional vasoregulatory mechanisms. HD patients char-
acteristically exhibit defective BP control in the face of
ultrafiltration requirements (due to impaired baroreflex
sensitivity, etc.). This leaves patients at the end of HD with
BP, which becomes increasingly dependant on a maintained
cardiac output,10 further increasing the risk of myocardial
hypo perfusion as a result of hypotension.
All of these factors coexist with the well-recognized high
prevalence of ‘conventional’ large vessel epicardial coronary
artery disease (CAD). The relative contributions of the macro
and micro cardiac circulations to the genesis of dialysis-
induced ischemia do however remain unclear. Indeed, several
studies have reported no correlation between the develop-
ment of intradialytic ST depression and angiographically
proven CAD.11,12
MYOCARDIAL STUNNING AND HIBERNATION
In patients with CAD, but without chronic kidney disease,
transient myocardial ischemia may lead to left ventricular
(LV) dysfunction that can persist after the return of normal
perfusion. This prolonged dysfunction is known as myocar-
dial stunning.13 Repetitive episodes of ischemia can be
cumulative and have been shown to lead to prolonged LV
dysfunction. Myocardial stunning has been well described, in
the non-dialysis patient population, as a causative mechan-
ism for heart failure.14
Repeated episodes of myocardial ischemia lead to a
spectrum of disease encompassing myocardial stunning
through to myocardial hibernation and ending in myocardial
remodeling and scarring, with irreversible loss of contractile
function. Standard conventional thrice weekly HD as a cause
of repetitive myocardial stunning might lead to such a
process, resulting in chronic LV dysfunction. Myocardial
hibernation may represent a functional adaptation to chronic
hypoperfusion that can be reversed with restoration of
regional MBF (the ‘smart heart’ hypothesis).15 There is
evidence to suggest that hibernating myocardium is still
highly vulnerable to increases in demand or reductions in
oxygen supply, such as further hemodynamic stress during
HD. Therefore, ongoing recurrent episodes of ischemia
precipitated by HD may have negative consequences on this
adaptive balance leading to further myocardial injury and
eventual non-viable myocardium with irreversible reduction
in LV function.
DIALYSIS-INDUCED ISCHEMIA
Initial evidence of HD-induced myocardial ischemia has
previously come from electrocardiogram-based studies,
augmented by some limited isotopic perfusion imaging work
and observations relating to humoral biomarkers of cardiac
injury. Around 10 studies, after the initial report by Zuber
et al.,8 have demonstrated silent ST-segment depression
occurring during dialysis. These studies report occurrence of
dialysis-induced ST depression at rates that vary between 15
and 40%. Singh et al.16 assessed dialysis-induced ischemia
using sestamibi single-photon emission computed tomogra-
phy. In an unselected group of 10 dialysis patients who were
not known to have CAD, seven developed perfusion defects
during dialysis.
It is well recognized that cardiac troponins are often
elevated in dialysis patients, and that elevated levels predict
mortality. Although there was initial debate about the origin
of elevated troponins in renal disease, it is now clear that the
troponins are cardiac in origin, and it is the intact molecule
(as opposed to smaller fragments) that are detected by the
current assays. Some evidence exists that HD itself is related
to an increase in troponin levels.17 Several authors have
reported significant rises in cardiac troponin T (cTnT) post-
dialysis, whereas others have found no difference in pre- and
post-dialysis cTnT or cardiac troponin I (cTnI) levels, or
found that any difference that is observed disappears after
correction for hemoconcentration resulting from ultrafiltra-
tion. However, measuring post-dialysis troponin levels to
look for dialysis-induced ischemia may be flawed; it is well
recognized that plasma troponin levels may only become
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Figure 1 |Physiological responses to hemodialysis that might
be involved in the pathogenesis of IDH. IDH, intradialytic
hypotension.
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elevated after 6 to 12 h following an episode of ischemia. This
is beyond the window of blood sampling utilized in most of
the currently available studies. We have previously reported
higher pre-HD serum cTnT levels in patients prone to IDH as
compared with patients without significant hypotensive
response to HD. However, this does not necessarily reflect
dialysis-induced cTnT release and alternatively could be
explained by a greater cardiac disease burden in those
unstable patients.18 Hung et al.19 demonstrated that cTnI
rose significantly when measured 44 h after dialysis sessions
complicated by IDH (that is, measured at the subsequent
dialysis session) as compared with sessions in which patients
were stable.
DIALYSIS-INDUCED MYOCARDIAL STUNNING
Hemodialysis-induced ischemia, and myocardial stunning,
can be studied by echocardiographic means, looking for the
development of LV regional wall motion abnormalities
(RWMAs), with resolution after the cessation of the
hemodynaic stress of HD being characteristic of stunning.
The development of new LV RWMAs during physiological or
pharmacological stress occurs in response to ischemia, and its
onset precedes that of symptoms and electrocardiographic
changes. This principle underlies dobutamine stress echo-
cardiography. A recent study using H2
15O positron emission
tomography to measure MBF during dialysis demonstrated
that HD precipitates reductions in MBF to the levels at peak
dialytic stress consistent with the development of myocardial
ischemia (Figure 2). This was true even in the absence of
angiographically significant coronary disease (all patients
having undergone coronary angiography to exclude CAD).
The same study also confirmed that HD-induced segmental
LV dysfunction (measured echocardiograhically) correlates
with matched reduction in segmental MBF.20
Hemodialysis is capable of inducing subclinical myocar-
dial ischemia, and this phenomenon is related to ultrafiltra-
tion and hemodynamic instability. We have recently
concluded a study of 70 prevalent HD patients. HD-induced
myocardial stunning was assessed utilizing serial intradialytic
echocardiography and RWMA measurement to evaluate the
extent and severity of HD-induced cardiac injury.21,22 This
study identified around 60% of patients as developing
HD-induced myocardial stunning. In multivariate analysis
intradialytic reduction in BP and ultrafiltration volume
both independently determined the propensity to suffer
HD-induced cardiac injury. Fluid removal of 1 over a
standard 4 h HD session conferred a five times greater risk
of developing HD-induced myocardial stunning, this risk
rose to 26 times greater for a 2 ultrafiltration volume, with
consequently higher ultrafiltration rate. Presumably this
additional effect of ultrafiltration volumes, over and above
effects on BP, relates to potential hemoconcentration with
increasing microcirculatory shear stress and reduced micro-
perfusion leading to myocardial ischemia. Currently it is not
clear how the risk of a high ultrafiltration volume can be
ameliorated by the modification of the dialysis session to
reduce ultrafiltration rate. The only other associated factors
of significance from this model were patient age and cTnT
level (pre-dialysis levels almost three times higher in affected
patients). These four factors displaced all other standard
biochemical/hematological, historical and dialysis treatment-
based variables.
The importance of hemodynamic stability in the patho-
genesis of HD-induced ischemic injury is illustrated in two
studies of modification of dialysis technique to assist in the
maintenance of BP without the alteration of ultrafiltraion
volume removal. In the first of these studies we compared
standard bicarbonate HD with a biofeedback technique
(Hemocontrol, Gambro-Hospal, Mirandola, Italy) that
responded to significant declines in relative blood volume
by temporarily reducing ultrafiltration rate and increasing
dialysate conductivity.23 This was performed within defined
limits to ensure total fluid, and sodium depuration was
unaffected. Biofeedback dialysis (BFD) has been shown to
reduce IDH in several studies. In the second study in a
different group of stable chronic HD patients, we compared
standard dialysis with dialysate temperatures of 371C and
cooled dialysate at 351C.24 This latter intervention, well
recognized to reduce IDH, has the advantages that it is
extremely simple to perform, is available on all dialysis
monitors and does not incur additional treatment costs,
although the long-term tolerability of such a significant
reduction in dialysate temperature may represent a problem.
Both studies contained small numbers of patients, which
were relatively short-term focusing on the acute effects of the
interventions and were prospective and crossover in design.
In both studies, a significant number of new RWMAs
occurred during standard dialysis. By improving mean BP
and reducing IDH episodes with either BFD or reduced
temperature dialysis, a significant reduction in the number of
new RWMAs was observed. Although most RWMAs
improved after the cessation of HD, approximately 30% of
affected regions still displayed abnormal motion at the
relatively short 30min post-dialysis recovery period. Effect of
a longer recovery period is currently unknown. In addition to
Figure 2 |Patient undergoing assessment of intradialytic
segmental myocardial perfusion using cardiac positron
emission tomography.
Kidney International (2009) 76, 371–375 373
CW McIntyre: Effects of hemodialysis on cardiac function min i rev iew
segmental changes we also observed a higher overall LVEF,
with both BFD and cool dialysis. It may be that either the
higher mean BP or the reduction in IDH was responsible for
the reduction in the incidence of RWMAs, although it is also
conceivable that the effects of both of these factors were
synergistic, with IDH that occurs at a lower mean BP
potentially having a greater detrimental effect on myocardial
perfusion. In positron emission tomography-based study of
intradialytic MBF, the use of BFD resulted in reduced
instability only in the later part of HD and this was associated
with a significantly better recovery of MBF post-HD,20
supporting the contention that at least with BFD the
beneficial changes with respect to MBF are linked to
maintenance of intradialytic BP.
The potential role for a combination of microcirculatory
dysfunction, ischemic potential of reduced peripheral arterial
compliance, in addition to the other non-atheromatous
consequences of the uremic milieau, is further suggested by
recent study of pediatric HD patients. We studied 12 children
established on maintenance HD. This represented a good
model of uremic cardiovascular disturbances, in the absence
of conventional cardiovascular risk factors. The dialysis
treatments were characterized by particularly large ultrafil-
tration requirements and relative dialysis-induced hypoten-
sion. A high proportion of the children (11/12 patients)
exhibited evidence of acute dialysis-induced myocardial
stunning (utilizing similar methodologies to the above
studies), with some biochemical evidence of cardiac injury.25
LONG-TERM CONSEQUENCES OF RECURRENT HD-INDUCED
ISCHEMIC INJURY
Twelve month follow-up of HD patients, initially studied
with dialysis-based echocardiography to identify those
suffering from HD-induced cardiac injury, revealed signifi-
cant effects on cardiac structure, function and patient
survival. Those patients who did not develop HD-induced
myocardial stunning (27/70) by 1 year of follow-up had
experienced only one significant cardiac event, no change in
segmental shortening fraction, no reduction in overall LVEF,
and 100% survival. This was in stark contrast to the group
characterized by the development of dialysis-induced myo-
cardial stunning (43/70), where 28% of the patients (12/43)
had died. In those patients who survived to 1 year follow-up,
there had been a rough halving of shortening fraction of
those ventricular segments identified as suffering dialysis-
based RWMA and a reduced overall LVEF (at rest and at peak
during HD) by around 10% (absolute) in conjunction with
an attendant significant increase in cTnT levels.22
Intadialytic BP was significantly lower in patients who
stunned c.f. baseline, whereas in patients who did not, their
hemodynamic tolerability of HD was unchanged. However,
the only patients that had a significant deterioration in their
BP (systolic and diastolic) during HD after 12 months were
in the group that developed regional fixed systolic reductions
of460%. This is not attributable simply to volume overload.
A small subset of patients with below average ultrafiltration
volumes had significant reductions in SBP. In addition, SBP
at the end of HD is primarily determined by cardiac output10
and therefore it is likely that the absolute reduction in SBP
seen is at least in part secondary to the reduction in LVEF.
IDH is known to be associated with increased mortality.26
Given the underlying vulnerability of hibernating myocar-
dium to increases in demand, coupled with decreased
coronary flow reserve in HD patients, it may be that this
adaptive process actually leads to further segmental injury by
exacerbating intradialytic instability. This may be one of the
reasons that prevalence of heart failure is so high, and
survival so poor in HD patients that start to develop
myocardial contractile dysfunction.
Survival may also be determined by the incidence of
intradialytic and post-dialytic ventricular arrhythmias. In 40
patients, serial echocardiography was augmented with 12 lead
Holter recording to capture pre-, intra-, and post-dialytic
electrocardiogram changes over a 48 h period. Dialysis-
induced myocardial stunning was associated with an
increased rate of intradialytic and post-dialytic ventricular
arrhythmias,21 suggesting that this phenomenon may be
important in both of interlinked major identifiable caused of
CV mortality in HD patients (sudden cardiac death and heart
failure).
CONCLUSIONS
The procedure of HD exerts significant acute stress upon the
cardiovascular system. There is an increasing body of
evidence to suggest that subclinical ischemia is precipitated
by dialysis, and that this is a common phenomenon. Episodes
of ischemia may potentially have a role in the development of
cardiac failure, and as a trigger for arrhythmias. Therefore,
reducing the acute impact of dialysis on the cardiovascular
system would seem to be a desirable therapeutic target.
A variety of interventions, both dialysis based (hemodia-
filtration, refinements of dialysate cooling, dialysate magne-
sium concentration manipulation, hypoxia avoidance,
isothermic HD, and quotidian HD) and non-dialysis based,
predominantly focused on reduction in required ultrafiltra-
tion volume (intensive insulin therapy in diabetics to reduce
hyperglycemia with subsequent free water ingestion and
improved sodium management) are currently under active
investigation. These studies are designed to both further
elucidate the pathophysiology involved and identify and
select optimal therapies for future large scale RCT study of
‘hard’ end points. This is of particular importance given the
almost universal lack of effectiveness of other cardiovascular
interventions developed within the non-dialysis-based popu-
lation. It appears reasonable that in selecting a therapeutic
change, synthesized within an enhanced understanding of the
pathophysiological processes involved in the major cause of
death of our HD patients, we may have a realistic chance of
making an impact on the current appalling survival figures.
Clearly, though, this requires focused large-scale collaborative
study of interventions with significant potential to be both
high impact and cost effective.
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